US · Healthcare · Biotechnology
EPS came in at -0.53 against a street estimate of -0.50 — a miss of 5.7%.
Analysts rate Cogent Biosciences Inc a buy (9 buy, 3 hold, 0 sell out of 12) with an average price target of $54.25.
| Fund | Stake |
|---|---|
| FMR Inc | 13.53% |
| BlackRock Inc | 9.39% |
| Deerfield Management Co | 5.29% |
| Vanguard Portfolio Management, LLC | 4.29% |
| Vanguard Capital Management, LLC | 4.04% |
| HHG PLC | 3.49% |
| State Street Corp | 3.31% |
| Fairmount Funds Management LLC | 3.22% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-11 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-23 |
| Annual report FY2025 | 2026-02-17 |
| Results announced · Q1 2026 | 2026-02-17 |
| Company announcement · Q4 2025 | 2025-12-08 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cogent Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.